Game Changer: Once-Weekly Insulin Revolutionizes Diabetes Care, First Launched in India

A groundbreaking shift in diabetes management is officially underway as Novo Nordisk once-weekly insulin, Awiqli (insulin icodec-abae), hit the Indian market yesterday, July 9, 2026, approved for both Type 1 and Type 2 Diabetes. This follows its landmark US FDA approval for Type 2 Diabetes in March 2026, marking the first time patients can reduce their annual insulin injections from 365 daily jabs to a mere 52. The Danish drugmaker's innovation promises to drastically simplify treatment routines and boost adherence for millions globally. The burden of daily insulin injections has long been a major hurdle for diabetes patients, often leading to missed doses and poorer health outcomes; Awiqli directly tackles this by offering a more convenient, long-acting solution. Clinical trials under the ONWARDS program demonstrated Awiqli efficacy, showing superior or non-inferior HbA1c reduction compared to daily basal insulin, though concerns about potential hypoglycemia, particularly for Type 1 Diabetes, had initially impacted its broader US approval. With India alone having over 101 million people living with diabetes, this weekly regimen offers a critical leap forward in managing a widespread chronic condition. While Novo Nordisk gains a first-mover advantage, competitor Eli Lilly is hot on its heels with its own once-weekly insulin candidate, efsitora alfa, currently in late-stage trials and expected to seek regulatory approval soon. The market is now poised for an exciting competitive landscape that could redefine insulin therapy, pushing further innovations like advanced Continuous Glucose Monitoring and smart insulin delivery systems. Patients can look forward to a future where managing diabetes is less about daily struggles and more about living life.